A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease

Patients with longstanding alopecia areata who have cycled through prior clinical encounters and been told that no meaningful treatment options exist represent a distinct and emotionally complex patient population. By the time such individuals present to a dermatologist, they have often developed an adaptive relationship with their hair loss: wearing hairpieces or scalp coverings as part of a daily routine, avoiding settings in which their alopecia might be visible, and-critically-having long since stopped expecting medicine to offer anything new. The psychological armor these patients have constructed is understandable and appropriate given the advice they received, but it also means that re-engaging them in treatment planning requires care and credibility.

The clinician must not only introduce the existence of effective new therapies but must also counteract years of accumulated hopelessness in a way that feels grounded rather than oversold.

When a patient in this category is identified-whether through a scheduled consultation or, as sometimes happens, incidentally during a skin exam performed for a separate indication-treatment selection is guided by the same shared decision-making framework applied to any new systemic therapy candidate, with particular attention to the patient's comorbidities, existing medication burden, and personal preferences around dosing. Ritlecitinib, with its straightforward once-daily oral administration and well-characterized safety profile in both adult and adolescent populations, has emerged as a natural fit for patients who want to integrate a new medication as seamlessly as possible into an existing routine. Comorbidities that limit eligibility for other agents may further narrow the decision, and the prescribing dermatologist must review each option carefully before making a recommendation. For patients who have waited years for a solution, setting realistic expectations about the 6- to 12-month timeline to visible regrowth is essential-hope grounded in honesty is more durable than hope built on overpromising.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, describes a patient he identified during a routine skin examination who had been wearing a hairpiece for many years after being told there was nothing medicine could do for her AA. Aboul-Fettouh walks through the clinical and practical factors that guided the decision to initiate ritlecitinib-including comorbidities that precluded other agents, her strong preference for once-daily dosing. and the particular emotional significance of reintroducing genuine therapeutic hope into a case that had previously been framed, incorrectly, as untreatable.